A
Adicet Bio, Inc. (ACET)
NCM – Real vaqt narxi. Valyuta: USD
8.24
+0.01 (0.18%)
Bozor ochiq: Aug 12, 2026, 1:52 PM EDT
8.48
+0.25 (3.03%)
Oldingi bozordan keyin: Aug 11, 2026, 4:22 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
8.24
+0.01 (0.18%)
Bozor ochiq: Aug 12, 2026, 1:52 PM EDT
8.48
+0.25 (3.03%)
Oldingi bozordan keyin: Aug 11, 2026, 4:22 PM EDT
Adicet Bio, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda avtoimmunitet kasalliklari va saraton uchun allogen gamma delta T-hujayra terapiyalarini kashf qiladi va ishlab chiqadi. Kompaniyaning yetakchi mahsulot nomzodi, prulacabtagene leucel (prula-cel), avtoimmunitet kasalliklarini davolash uchun CD20 ni nishonga olgan CAR ni ifodalovchi allogen gamma delta T-hujayra terapiyasidir. Shuningdek, u prostata-maxsus membran antigenini nishonga olgan genetik tahrirlangan va zirhlangan klinik nomzod ADI-212 ni ishlab chiqadi. Kompaniya 2014 yilda tashkil etilgan va Boston, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Blake Aftab Ph.D. | Senior VP & Chief Scientific Officer |
| Dr. Donald Healey Ph.D. | Chief Technology Officer |
| Dr. Julie Maltzman M.D. | Chief Medical Officer |
| Dr. Lloyd Klickstein M.D., Ph.D. | Interim Chief Medical Officer & Director |
| Mr. Brian Nicholas Harvey M.B.A. | Chief Financial Officer |
| Mr. Chen Schor BA, CPA, M.B.A. | CEO, President & Director |
| Ms. Amy Locke | Chief Human Resource Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-05 | 8-K | acet-20260805.htm |
| 2026-08-05 | 10-Q | acet-20260630.htm |
| 2026-06-18 | 8-K | acet-20260617.htm |
| 2026-05-20 | 10-K/A | acet-20251231.htm |
| 2026-05-13 | S-8 POS | 2026_s-8_pos.htm |
| 2026-05-13 | 8-K | acet-20260513.htm |
| 2026-05-13 | 10-Q | acet-20260331.htm |
| 2026-04-29 | DEFA14A | acet-20260429.htm |
| 2026-04-29 | DEF 14A | acet-20260429.htm |
| 2026-04-29 | ARS | acet-2025_annual_report.pdf |